Breaking News Instant updates and real-time market news.

GM

General Motors

$40.95

0.14 (0.34%)

17:06
12/17/17
12/17
17:06
12/17/17
17:06

GM facing $1B reckoning in ignition-switch settlement, WSJ reports

General Motors faces a possible payout of $1B in stock to address claims regarding the company's ignition-switch crises, according to The Wall Street Journal. The trial is set to start Monday and centers on whether GM can stop a deal reached in August between ignition-switch plaintiffs and a trust representing creditors of so-called Old GM, the assets the carmaker left behind as part of its government rescue and restructuring, the publication noted. Reference Link

  • 09

    Jan

  • 16

    Jan

GM General Motors
$40.95

0.14 (0.34%)

12/01/17
LEHM
12/01/17
NO CHANGE
Target $57
LEHM
Overweight
Barclays ups GM price target to $57 after tech day
Barclays analyst Brian Johnson raised his price target for General Motors (GM) to $57 from $55 following yesterday's tech day. The automaker closed yesterday down 72c to $43.09. While some view GM's target of commercially launching at scale autonomous ridesharing in dense urban environments in 2019 as an unrealistic target, similar to the timelines pushed by Tesla (TLSA), time with management indicated this seems possible, Johnson tells investors in a research note. GM's technology is real, and the company has a fail-safe with the autonomous vehicles to be monitored by humans at control centers, the analyst contends. The tech day reinforced Johnson's view that GM has first mover advantage in mobility. He believes the shares are due for a "multiple re-rating" and reiterates an Overweight rating on GM.
12/01/17
SBSH
12/01/17
NO CHANGE
Target $60
SBSH
Buy
Citi more confident in $134 long-term upside case for GM shares
Citi analyst Itay Michaeli says he left General Motors' investor event yesterday with greater conviction on his thesis and prior $134 long-term potential upside case for the stock. The analyst attributes yesterday's share pullback to some "sell the news" and mixed feedback from media test rides in the GM autonomous vehicles, which the analyst views as a "non-issue." He believes GM's event essentially introduced a new industry, autonomous urban networks, that's moving quickly towards commercialization. He sees the market as having a significant total addressable market of "well into hundreds of billions, or higher." Michaeli thinks GM shares "stand to re-rate meaningfully higher." He keeps a Buy rating on the stock with a $60 price target.
12/01/17
DBAB
12/01/17
NO CHANGE
Target $52
DBAB
Buy
GM shares price in very little for mobility business, says Deutsche Bank
Deutsche Bank analyst Rod Lache says that if General Motors' autonomous mobility plans come to fruition, it could have "profound implications across many Industries." Following yesterday's event, the analyst continues to believe that very little of the mobility business is reflected in GM shares. His $52 price target assumes "just" $10 for GM's autonomous mobility business. The U.S. business alone could conservatively be worth at least $20 per share, and on a global basis it could be worth $40 per share, Lache tells investors in a research note. He keeps a Buy rating on GM.
12/08/17
PIPR
12/08/17
UPGRADE
Target $30
PIPR
Overweight
Meritor upgraded to Overweight from Underweight at Piper Jaffray
Piper Jaffray analyst Alexander Potter double upgraded Meritor (MTOR) to Overweight from Underweight and raised his price target for the shares to $30 from $12. The analyst elevated both Meritor and General Motors (GM) to top pick status in the Autos, Trucks, and Advanced Mobility space. Allison Transmission (ALSN) is still Potter's highest conviction Underweight rating. Geographic expansion, market share gains, and electric vehicle products could help Meritor achieve growth, Potter tells investors in a research note. He sees the company's fiscal 2018 guidance, which implies growth of about 9% year-over-year, as "modest" given the cyclical tailwinds in the U.S. truck market.

TODAY'S FREE FLY STORIES

ALB

Albemarle

$117.91

-9.04 (-7.12%)

, SQM

SQM

$59.02

-0.53 (-0.89%)

08:39
01/19/18
01/19
08:39
01/19/18
08:39
Recommendations
Albemarle, SQM, FMC Corporation analyst commentary  »

Albemarle price target…

ALB

Albemarle

$117.91

-9.04 (-7.12%)

SQM

SQM

$59.02

-0.53 (-0.89%)

FMC

FMC Corporation

$90.17

-3.69 (-3.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 28

    Feb

  • 07

    Mar

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

08:38
01/19/18
01/19
08:38
01/19/18
08:38
Hot Stocks
Breaking Hot Stocks news story on Schlumberger »

Schlumberger says will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

CARA

Cara Therapeutics

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Cara Therapeutics initiated  »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMP

Ameriprise

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Recommendations
Ameriprise analyst commentary  »

Ameriprise price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

PCRX

Pacira

$39.10

-1.2 (-2.98%)

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Pacira initiated  »

Pacira initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 15

    Feb

  • 06

    Apr

VNDA

Vanda

$14.25

-0.2 (-1.38%)

08:37
01/19/18
01/19
08:37
01/19/18
08:37
Initiation
Vanda initiated  »

Vanda initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

08:36
01/19/18
01/19
08:36
01/19/18
08:36
Hot Stocks
Schlumberger says intends to maintain presence in Venezuela »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

, LGF.B

Lionsgate

$32.84

2.46 (8.10%)

08:34
01/19/18
01/19
08:34
01/19/18
08:34
Recommendations
Lionsgate, Lionsgate analyst commentary  »

Lionsgate price target…

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

LGF.B

Lionsgate

$32.84

2.46 (8.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

HMNY

Helios and Matheson

$8.14

0.41 (5.30%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Hot Stocks
MoviePass announces MoviePass Ventures to co-acquire films »

MoviePass, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$32.75

2.09 (6.82%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Recommendations
Ichor Holdings analyst commentary  »

Ichor Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ABMD

Abiomed

$225.89

1.76 (0.79%)

08:31
01/19/18
01/19
08:31
01/19/18
08:31
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

GTXI

GTx

$12.65

0.15 (1.20%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Options
Three new option listings on January 19th »

New option listings for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Hot Stocks
Oramed CEO: Oral GLP-1 analog development is rapidly proceeding »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
SF Fed's Williams is being considered for the Vice Chair spot »

SF Fed's Williams is…

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
Breaking General news story  »

Atlanta Federal Reserve…

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

08:29
01/19/18
01/19
08:29
01/19/18
08:29
Hot Stocks
AstraZeneca reports Fasenra receives approval in Japan »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

SYF

Synchrony

$37.30

-0.76 (-2.00%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Technical Analysis
Technical Take: Synchrony falls after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SM

SM Energy

$25.69

-0.93 (-3.49%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Conference/Events
SM Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

SBNY

Signature Bank

$153.44

5.39 (3.64%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Signature Bank analyst commentary  »

Signature Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$61.84

0.67 (1.10%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

, STRA

Strayer

$92.18

-0.64 (-0.69%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Strayer to host special shareholder meeting »

Special shareholder…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

STRA

Strayer

$92.18

-0.64 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.